Gyre Therapeutics, Inc.

Equities

GYRE

US4037831033

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
11.04 ^USD	0.00%		-1.60%	-57.03%

May. 31	Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	MT
May. 30	Gyre Pharmaceuticals Receives IND Approval from China?s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension	CI

Gyre Therapeutics, Inc. and Beijing Continent Pharmaceuticals Co., Ltd. Announce the Resignation of Charles Wu as Member of the Board of Directors. Effective on January 15, 2024

December 15, 2023 at 04:22 pm EST

In connection with his resignation and departure from Gyre Therapeutics, Inc., Dr. Charles Wu also resigned as a member of the board of directors of the Company. and as a member of the board of directors of Beijing Continent Pharmaceuticals Co. Ltd., of which the Company holds an indirect controlling interest, each effective on January 15, 2024.

Latest news about Gyre Therapeutics, Inc.

Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	May. 31	MT
Gyre Pharmaceuticals Receives IND Approval from China?s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension	May. 30	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing	Apr. 03	MT
Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises	Mar. 26	MT
Gyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Gyre Therapeutics Announces Appointment of Rodney L. Nussbaum to the Board of Directors and Member of Audit Committee	Mar. 21	CI
Gyre Therapeutics, Inc. Announces Board Changes	Jan. 19	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Jan. 12	CI
Gyre Therapeutics, Inc. Announces CEO Changes, Effective January 15, 2024	Dec. 15	CI
Gyre Therapeutics, Inc. and Beijing Continent Pharmaceuticals Co., Ltd. Announce the Resignation of Charles Wu as Member of the Board of Directors. Effective on January 15, 2024	Dec. 15	CI
Gyre Therapeutics, Inc. Announces Management Changes	23-10-30	CI
Gyre Therapeutics, Inc. Announces Management Changes	23-10-30	CI
Gyre Therapeutics, Inc. Announces CEO Changes	23-10-30	CI
Gyre Therapeutics, Inc. Announces Management Changes	23-10-30	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI

Chart Gyre Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GYRE THERAPEUTICS, INC.	-57.03%	986M
MODERNA, INC.	+34.01%	52.85B
IQVIA HOLDINGS INC.	-8.02%	38.87B
LONZA GROUP AG	+34.86%	38.24B
CELLTRION, INC.	-11.12%	26.79B
ICON PUBLIC LIMITED COMPANY	+12.56%	26.16B
ALNYLAM PHARMACEUTICALS, INC.	-19.62%	19.9B
UNITED THERAPEUTICS CORPORATION	+39.18%	13.18B
MEDPACE HOLDINGS, INC.	+31.47%	12.24B
BIO-TECHNE CORPORATION	-3.40%	11.79B

Other Biotechnology & Medical Research